Image for post
Image for post

Professor Jørgen Jahnsen and PhD student Kristian Espeland of Akershus University Hospital and University of Oslo are responsible for a new clinical trial which aims to improve symptoms and control the inflammation of Crohn’s disease using Gliolan medication in combination with blue-light photopheresis. This approach will selectively cause the death of pro-inflammatory cells which contribute to the inflammatory bowel disease, whilst showing minimal short- and long-term side effects.

Inflammatory bowel disease (IBD) occurs in two main forms: Crohn’s disease (CD) and ulcerative colitis. Both types of inflammatory bowel disease are chronic, immune-mediated diseases affecting the gastrointestinal tract, particularly the bowel.

The exact cause of Crohn’s disease is unknown, but there are several factors hypothesised to be involved, including genes, autoimmune responses to the body’s tissues, previous gastrointestinal infections or an imbalance in the gut bacteria. The underlying pathology of Crohn’s disease is a T-cell-mediated response (T-cells are important for the activation of immune cells), characterised by an overproduction of pro-inflammatory components, i.e. activated hyperproliferative T-cells. …


Research Outreach

Connecting science with society

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store